Richard Miller, M.D.
Principal executive officer pay for Richard Miller, M.D., by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Corvus Pharmaceuticals, Inc. (CRVS) FY2022–FY2025
Aligned: paid up as stock roseCAP -$326,168→$7,325,075 while $100 invested went $35.27→$905.88
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2022 | $524,239 | -$326,168 |
| FY2023 | $1.3M | $2.6M |
| FY2024 | $3.1M | $7.5M |
| FY2025 | $7.0M | $7.3M |
The company's "$100 invested" index ran $35.27 at FY2022 → $905.88 by FY2025 — an annualized return of 195.0%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 195.0%/yr at CRVS ( FY2022–FY2025). See the CEO track-record ranking for context.